David E. Lanfear, MD MS

@drjohnm I respectfully disagree, John. TOPCAT was neutral. Touting spironolactone for HFpEF relies on subgroup-analyses. We shouldn’t elevate any intervention to standard care based on this alone. It’s thus a logical error to mandate subsequent trials compare to unproven therapy.

It shocks me that people think billion-dollar companies should be allowed to clear a lower bar of regulatory approval. It's a head shaker. Another exhibit. A new heart failure drug finerenone was allowed to be tested against placebo instead of spironolactone. This is an egregious regulatory failure. Trust me: you want @VPrasadMDMPH on that wall. Lest you will have pricey less than ideal Rx. It's a malignant condition.

Heart Failure Awareness Week is here ❤️ From February 8–14, HFSA will be sharing trusted resources, practical tips, and easy-to-understand education focused on recognizing heart failure risk, understanding symptoms, and supporting heart health in everyday life. Whether patients are living with heart failure, caring for a loved one, or simply looking to learn more, this week is designed to inform, support, and empower. Encourage your patients to follow along!

Excited to share our new @NatRevCardiol review on the environmental #exposome in #HF risk and progression 🌍❤️ Led by @OmarHahad, this international collaboration connects pollution, climate, noise, light, metals, and the built environment with HF. shorturl.at/du0lb

Great kick off to #COMET-HF North American Investigator Meeting from @MyosinMD focused on the science behind omecamtiv mecarbil

A genetic variant in GRK4 significantly interacts with beta-blocker benefit in patients heart failure (and possibly other genetic variants as well): ascpt.onlinelibrary.wiley.com/doi/10.1111/ct… @ASCPTjournals @dlanfearMD @Ana04524295 @pgrnhub @cpicpgx @pkpdpg @accpcardprn @GenPrecisionMed

Really happy to share our introductory guide to cardio-obstetrics in the CCU! We hope this will contribute to exceptional care for these patients @radcliffeCARDIO @AmitGoyalMD @AnnGageMD @KayleShapero

Exciting news! Our latest research on dilated cardiomyopathy has just been published in Nature Genetics: rdcu.be/d0ZzH A huge thank you to our incredible HERMES collaborators for making this possible. hermesconsortium.org @drjamesware @SeanLZheng @AH_AlbertHenry

Harnessing the Plasma Proteome to Predict Mortality in Heart Failure Subpopulations @JulioChirinosMd @dlanfearMD @DrNancySweitzer @fwasselbergs #AHAJournals ahajrnls.org/4ijStb7

🚨 Our latest GWAS of heart failure subtypes is now out in Nature Genetics! rdcu.be/eb9O0 A massive global collaboration from HERMES Consortium involving >40 studies with >150,000 heart failure cases. @HERMESgenetics @tomlumbers 🧵 highlighting key findings 1/

Congestion🚰 assessment in HF: from symptoms, to weights, BNP, invasive pressures....now IVC area? Check out this and other late breakers planned for @HFSA in @JCardFail ‼️ @NirUrielMD @gtsayer @FudimMarat @dranulala @robmentz @Stanford_HF sciencedirect.com/science/articl…

Exciting times: HFH+MSU Health Science Research Building ground breaking. Congrats to our great HFH leaders, @SteveKalkanisMD , Adnan Munkarah MD, Robert Riney, and all our MSU partners.

Happy birthday, 45🇺🇸 🔜47

Honored to be part of this fantastic randomized trial showing similar benefits of home-based cardiac rehab vs. traditional. Thanks to steve, clinton and the whole preventive cardiology crew for letting be a part. urldefense.com/v3/__https://a…$

I’m proud to announce Dr. Jim Januzzi’s promotion to Chief Scientific Officer @BaimInstitute (formerly Harvard Clinical Research Institute or HCRI). BaimInstitute.org Dr. Januzzi is a brilliant clinical researcher and an academic superstar. His groundbreaking work in the field of biomarkers and congestive heart failure have earned him the respect and admiration of cardiologists around the world. His patients are fortunate to have him guiding their care @MGHMedicine which he will continue to do in his dual role. We value his tireless efforts and his dedication to Baim and its academic mission. We look forward to his contributions in shaping the academic and strategic vision of Baim in the years to come. Join me in congratulating Dr. Januzzi on his well deserved recognition and promotion!

@Babar_Basir Sounds eminently reasonable.

My opinion on the use of MCS has been the following since #NCSI 1. Routine use in AMI-CS (routine doesn’t mean 100%) 2. Selective use in HF-CS 3. Highly selective use in HR-PCI 4. Limited to no role in AMI w/o shock (I have never placed an MCS to “prevent” CS).

Nice overview of #pharmacogenetic recommendations in clinical practice guidelines for multiple therapeutic areas: cardiology, pain, general medicine, infectious disease, psych, neuro, oncology academic.oup.com/ajhp/advance-a… @ASHPOfficial @BousmanChad @mcleodhoward @SaraWattari @cc_pgx

Our turn! Today our PI is sharing latest findings in mitral valve disease biomarkers and omics at the #Biomarkers forum . Happy to share the floor with excellent speakers @ThomasThum_TH2 and @dlanfearMD in a brilliant session!

Outstanding work by Isabella Kardys, Marie de Bakker and friends, demonstrating proteomic derived panel outperforms clinical risk factors. academic.oup.com/ehjdh/article/…

Outstanding work by Isabella Kardys and crew. Congrats! Machine learning–based biomarker profile derived from 4210 serially measured proteins predicts clinical outcome of patients with heart failure academic.oup.com/ehjdh/article/…